Similarity of biotechnology-derived medicinal products: specific problems and new regulatory framework.
作者信息
Prugnaud Jean-Louis
出版信息
Br J Clin Pharmacol. 2008 Apr;65(4):619-20. doi: 10.1111/j.1365-2125.2007.03062.x. Epub 2007 Dec 17.
Abstract
摘要
相似文献
1
Similarity of biotechnology-derived medicinal products: specific problems and new regulatory framework.生物技术衍生药品的相似性：具体问题与新监管框架
Br J Clin Pharmacol. 2008 Apr;65(4):619-20. doi: 10.1111/j.1365-2125.2007.03062.x. Epub 2007 Dec 17.
2
A proposed European pharmacopeia monograph for continuous cell lines derived drugs.一项关于源自连续细胞系药物的欧洲药典专论提案。
Dev Biol Stand. 1989;70:113-24.
3
Global perspective on specifications for biotechnology products--perspective from Japan.生物技术产品规范的全球视角——来自日本的视角
Dev Biol Stand. 1997;91:15-23.
4
Development of specifications for biotechnology products--perspective from Europe.生物技术产品规范的制定——欧洲视角
Dev Biol Stand. 1997;91:25-30.
5
Nature Biotechnology responds.
Nat Biotechnol. 2014 Feb;32(2):132. doi: 10.1038/nbt.2822.
6
Can lifecycle management safeguard innovation in the pharmaceutical industry?生命周期管理能否保障制药行业的创新？
Drug Discov Today. 2018 Dec;23(12):1962-1973. doi: 10.1016/j.drudis.2018.10.008. Epub 2018 Oct 17.
7
The regulatory framework for similar biotherapeutic products in Cuba.古巴类似生物治疗产品的监管框架。
Biologicals. 2011 Sep;39(5):317-20. doi: 10.1016/j.biologicals.2011.08.005. Epub 2011 Sep 17.
8
Biosimilars and safety issues.生物类似药与安全性问题。
Leuk Lymphoma. 2009 Apr;50(4):656-8. doi: 10.1080/10428190802714248.
9
Biosimilars: considerations for an abbreviated pathway.生物类似药：简化审批途径的考量因素
Leuk Lymphoma. 2009 Apr;50(4):527-8. doi: 10.1080/10428190902853151.
10
Specifications from a biotechnology industry perspective.从生物技术产业角度来看的规格要求。
Dev Biol Stand. 1997;91:31-6.
引用本文的文献
1
Pharmacist Substitution of Biological Products: Issues and Considerations.药剂师替代生物制品：问题与考虑。
J Manag Care Spec Pharm. 2015 Jul;21(7):532-9. doi: 10.18553/jmcp.2015.21.7.532.
2
Choice of Starting Dose for Biopharmaceuticals in First-in-Human Phase I Cancer Clinical Trials.癌症首次人体I期临床试验中生物制药起始剂量的选择
Oncologist. 2015 Jun;20(6):653-9. doi: 10.1634/theoncologist.2015-0008. Epub 2015 May 11.
3
Minimising harm: human variation and adverse drug reactions (ADRs).减少伤害：人类差异与药物不良反应（ADR）
Br J Clin Pharmacol. 2008 Apr;65(4):451-2. doi: 10.1111/j.1365-2125.2008.03170.x.
Zotero 插件